Ultraviolet B exposure could influence the interpretation of serum S100? levels in patients with malignant melanoma

Vitzthum, J.; Dörr, Harald; Meineke, V.

doi:10.1111/j.1365-2133.2006.07737.x

Cited by 5 publications

(4 citation statements)

References 8 publications

(20 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Even up to 25% of the healthy normal population shows an increased S100B serum level. Vizthum et al (24) explain this phenomenon with an increase of the S100B serum levels after exposition to ultraviolet B irradiation.…”

Section: Discussionmentioning

confidence: 99%

18FDG-PET to assess recurrence and long term survival in patients with malignant melanoma

Wieder¹,

Tekin²,

Rosenbaum-Krumme³

et al. 2013

Nuklearmedizin

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

18FDG-PET to assess recurrence and long term survival in patients with malignant melanoma

Wieder¹,

Tekin²,

Rosenbaum-Krumme³

et al. 2013

Nuklearmedizin

View full text Add to dashboard Cite

show abstract

“…Significantly higher serum levels can be found in patients with liver cirrhosis or renal failure [15]. Interestingly 25% of healthy individuals can also have an increased S100B level, the fact that could be explained by an increased serum S100B level measured after UVB exposure of some individuals [17]. …”

Section: Discussionmentioning

confidence: 99%

Role of serum S100B and PET-CT in follow-up of patients with cutaneous melanoma

et al. 2011

View full text Add to dashboard Cite

BackgroundIncreased level of serum S100B can serve as a marker of metastatic spread in patients with cutaneous melanoma (CM). In patients with elevated S100 B and/or clinical signs of disease progression PET-CT scan is a valuable tool for discovering metastases and planning treatment.The aims of this study were to determine whether regular measurements of serum S100B are a useful tool for discovering patients with CM metastases and to evaluate the diagnostic value of PET-CT during the follow-up.MethodsFrom September 2007 to February 2010, 115 CM patients included in regular follow up at the Institute of Oncology Ljubljana were appointed to PET-CT. There were 82 (71.3%) patients with clinical signs of disease progression and 33 (28.7%) asymptomatic patients with two subsequent elevated values of S100B. Sensitivity, specificity, positive and negative predictive value (PPV, NPV) of S100B and PET-CT were calculated using standard procedures.ResultsDisease progression was confirmed in 81.7% of patients (in 86.5% of patients with clinical signs of disease progression and in 69.7% of asymptomatic patients with elevated S100B). Sensitivity, specificity, PPV and NPV of S100B was 33.8%, 90.9%, 96.0% and 17.5% in patients with clinical signs of disease progression. In 20.0% of patients increased serum S100B was the only sign of disease progression. Sensitivity and PPV of S100 in this group of patients were 100.0% and 69.7%.With PET-CT disease progression was diagnosed in 84.2% of symptomatic patients and in 72.7% of asymptomatic patients with elevated S100B. The sensitivity, specificity, PPV and NPV of PET-CT for symptomatic patients was 98.5%, 90.9%, 98.5% and 90.9% and 100%, 90.0%, 95.8% and 100% for asymptomatic patients with elevated S100.ConclusionsMeasurements of serum S100B during regular follow-up of patients with CM are a useful tool for discovering disease progression in asymptomatic patients. The value of its use increases if measurements are followed by extended whole body PET-CT.

show abstract

“…Melanoma is an aggressive malignancy, which kills a disproportionately large number of young people, and it is not surprising that significant and sustained efforts have been directed towards the improvement of its prevention, diagnosis and treatment 1–49 . The understanding of the development and regression of benign melanocytic proliferations such as naevi is important and may help to understand the pathogenesis of melanoma 50–59 .…”

Section: Naevi Melanoma Dermoscopy and Cutaneous Side‐effects Of Chmentioning

confidence: 99%

Report from the 67th Annual Meeting of the American Academy of Dermatology

Alexandroff

Graham‐Brown

2009

British Journal of Dermatology

View full text Add to dashboard Cite

The 67th Annual Meeting of the American Academy of Dermatology took place in San Francisco on 6-10 March 2009. The flavour of this busy but well-organized convention was a mixture of practical, hands-on teaching sessions, led and delivered by experts, with breakthrough cutting-edge scientific sessions. Aesthetic dermatology comprised a significant part of the meeting. It is impossible to encompass all the important presentations made at the meeting and satellite symposiums, but we highlight here a few medical pearls on dermoscopy, melanoma and oncology, inflammatory dermatoses and community-acquired methicillin-resistant Staphylococcus aureus. Our report is not intended as a substitute for reading the conference proceedings, educational session handouts, online updates and related references quoted in this article.

show abstract

Ultraviolet B exposure could influence the interpretation of serum S100? levels in patients with malignant melanoma

Cited by 5 publications

References 8 publications

18FDG-PET to assess recurrence and long term survival in patients with malignant melanoma

18FDG-PET to assess recurrence and long term survival in patients with malignant melanoma

Role of serum S100B and PET-CT in follow-up of patients with cutaneous melanoma

Report from the 67th Annual Meeting of the American Academy of Dermatology

Contact Info

Product

Resources

About